Bayer In The Market For Early-Stage R&D Deals
No Big Acquisitions Planned
Executive Summary
CEO Bill Anderson said that "the track record of the industry and late-stage acquisitions is really poor,” and Bayer was pursuing more preclinical and early-stage pacts instead.
You may also be interested in...
Deal Watch: Leo Pharma Adds Rare Dermatology Disorder Candidate In Timber Buyout
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
Regeneron Raises Possibility Of Quick CRL Resolution For High-Dose Eylea
On its Q2 earnings call, Regeneron said its 8mg formulation of aflibercept could obtain US FDA approval this quarter, despite receiving a complete response letter in June. Refiling’s fate tied to review of pozelimab.
All Systems Go At Almirall To Enter Tough Atopic Dermatitis Market With Ebglyss
Following a positive opinion from the CHMP, the Spanish company is hoping to launch its challenger to Dupixent in the EU before the end of the year.